


# Pharmaceutical Production and Related Technology Transfer



Intellectual  
Property and Trade



R&D  
Innovation



Technology  
Transfer



Improving Access



Financing



Monitoring and  
Reporting



World Health  
Organization



# Pharmaceutical Production and Related Technology Transfer



**World Health  
Organization**

Prepared for the WHO Department of Public Health, Innovation and Intellectual Property by Suerie Moon (Kennedy School of Government and School of Public Health, Harvard University).

This report forms part of the project entitled: Improving access to medicines in developing countries through technology transfer related to medical products and local production. It is implemented by the Department of Public Health Innovation and Intellectual Property of the World Health Organization (WHO/PHI) in partnership with the United Nations Conference on Trade and Development (UNCTAD) and the International Centre for Trade and Sustainable Development (ICTSD) with funding from the European Union (EU). The overall objective of the project is to increase access – especially for the poor in developing and least developed countries – to medicines, vaccines and diagnostics.

All reports associated with this project are available for free download from the following website: <http://www.who.int/phi/en/>

This publication has been produced with the assistance of the European Union. The contents of this publication are the sole responsibility of the World Health Organization and can in no way be taken to reflect the views of the European Union.

Editing and design by Inís Communication – [www.iniscommunication.com](http://www.iniscommunication.com)

#### WHO Library Cataloguing-in-Publication Data

Pharmaceutical production and related technology transfer: landscape report.

1.Essential drugs. 2.Pharmaceutical preparations. 3.Technology transfer. 4.Technology, Pharmaceutical. 5.Drug compounding. 6.Developing countries. I.World Health Organization.

ISBN 978 92 4 150235 1 (NLM classification: QV 704)

All rights reserved. Publications of the World Health Organization are available on the WHO web site ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site ([http://www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in France

© World Health Organization 2011

# Contents

|                                                                                             |    |
|---------------------------------------------------------------------------------------------|----|
| Abbreviations . . . . .                                                                     | iv |
| Acknowledgments . . . . .                                                                   | vi |
| Executive summary . . . . .                                                                 | 1  |
| 1. Introduction . . . . .                                                                   | 13 |
| 2. Methods . . . . .                                                                        | 20 |
| 3. Overview of local production of drugs in low- and middle-income<br>countries . . . . .   | 23 |
| 4. Findings on initiatives for local production and technology transfer . . .               | 26 |
| 5. Discussion and key issues . . . . .                                                      | 41 |
| 6. Recommendations and conclusions . . . . .                                                | 52 |
| References . . . . .                                                                        | 57 |
| Annex I: Technology transfer projects for local production . . . . .                        | 65 |
| Annex II: Technology transfer projects for local production . . . . .                       | 73 |
| Annex III: Voluntary licences for drugs (with and without<br>technology transfer) . . . . . | 75 |
| Annex IV: Interviewed individuals . . . . .                                                 | 78 |
| Annex V: Interview protocol . . . . .                                                       | 79 |

## Abbreviations

|          |                                                                                                                       |
|----------|-----------------------------------------------------------------------------------------------------------------------|
| AIDS     | acquired immunodeficiency syndrome                                                                                    |
| API      | active pharmaceutical ingredient                                                                                      |
| ARV      | antiretroviral                                                                                                        |
| AusAID   | Australian Government Overseas Aid Program                                                                            |
| BMZ      | German Federal Ministry for Economic Cooperation and Development                                                      |
| BuZa     | Ministerie van Buitenlandse Zaken (The Netherlands International Cooperation Agency)                                  |
| cGMP     | current good manufacturing practice                                                                                   |
| CIDA     | Canadian International Development Agency                                                                             |
| Danida   | Danish International Development Agency                                                                               |
| DEG      | Deutsche Investitions- und Entwicklungsgesellschaft                                                                   |
| DFID     | United Kingdom Department for International Development                                                               |
| DNDi     | Drugs for Neglected Diseases initiative                                                                               |
| EAC      | East African Community                                                                                                |
| ECOWAS   | Economic Community of West African States                                                                             |
| EMA      | European Medicines Agency                                                                                             |
| EU       | European Union                                                                                                        |
| FDC      | fixed-dose combination                                                                                                |
| FIOCRUZ  | Oswaldo Cruz Foundation                                                                                               |
| GFATM    | Global Fund to Fight AIDS, TB and Malaria                                                                             |
| G-FINDER | Global Funding of Innovation for Neglected Diseases                                                                   |
| GCP      | good clinical practice                                                                                                |
| GLP      | good laboratory practice                                                                                              |
| GMP      | good manufacturing practices                                                                                          |
| GNI      | gross national income                                                                                                 |
| GSK      | GlaxoSmithKline                                                                                                       |
| GSPA-PHI | Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property                             |
| GIZ      | Gesellschaft für Internationale Zusammenarbeit (Germany)                                                              |
| HIV      | human immunodeficiency virus                                                                                          |
| ICH      | International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use |
| ICTSD    | International Centre for Trade and Sustainable Development                                                            |
| IFC      | International Finance Corporation                                                                                     |

|        |                                                                           |
|--------|---------------------------------------------------------------------------|
| IFPMA  | International Federation of Pharmaceutical Manufacturers and Associations |
| IoWH   | Institute for OneWorld Health                                             |
| IPC    | Interagency Pharmaceutical Coordination Group                             |
| IPS    | Aga Khan Fund for Economic Development-Industrial Promotion Services      |
| JICA   | Japanese International Cooperation Agency                                 |
| LDC    | least developed country                                                   |
| LIC    | low-income country                                                        |
| MMV    | Medicines for Malaria Venture                                             |
| MSF    | Médecins Sans Frontières                                                  |
| NGO    | nongovernmental organization                                              |
| Norad  | Norwegian Agency for Development Cooperation                              |
| NIH    | United States National Institutes of Health                               |
| OECD   | Organisation for Economic Co-operation and Development                    |
| OTECI  | Office Technique d'Études et de Coopération Internationale                |
| PICS   | Pharmaceutical Inspection Cooperation Scheme                              |
| R&D    | research and development                                                  |
| SACU   | Southern African Customs Unit                                             |
| SADC   | Southern African Development Community                                    |
| SAGMA  | Southern African Generics Medicines Association                           |
| SIDA   | Swedish International Development Agency                                  |
| TB     | tuberculosis                                                              |
| TRIPS  | WTO Agreement on Trade-Related Aspects of Intellectual Property Rights    |
| UN     | United Nations                                                            |
| UNAIDS | United Nations Programme on HIV/AIDS                                      |
| UNCTAD | United Nations Conference on Trade and Development                        |
| UNDP   | United Nations Development Programme                                      |
| UNFPA  | United Nations Population Fund                                            |
| UNICEF | United Nations Children's Fund                                            |
| UNIDO  | United Nations Industrial Development Organization                        |
| USAID  | United States Agency for International Development                        |
| WHO    | World Health Organization                                                 |
| WIPO   | World Intellectual Property Organization                                  |
| WTO    | World Trade Organization                                                  |

## Acknowledgments

The author wishes to thank peer reviewers Wilbert Bannenberg, Cheri Grace and Xavier Seuba for insightful and constructive comments. She also thanks Zafar Mirza, Malebona Precious Matsoso, Gina Vea at the World Health Organization (WHO), and experts Frederick Abbott, Kiyoshi Adachi, Ermias Biadgleng, Padmashree Gehl Sampath, Cheri Grace, Elodie Jambert, Warren Kaplan, Pedro Roffe and Christoph Spennemann for helpful guidance and comments on earlier drafts of this report. She is grateful to Alyssa Yamamoto for excellent research assistance. Finally, she benefited greatly from the comments and discussion among participants at the International Centre for Trade and Sustainable Development (ICTSD)–United Nations Conference on Trade and Development (UNCTAD) African Dialogue on Technology Transfer for Local Production of Drugs and Vaccines (organized with the support of WHO and the European Commission), 10–11 December 2009, Cape Town, South Africa; and the Latin American Dialogue on Technology Transfer for Local Manufacturing of Drugs and Vaccines (organized by ICTSD and UNCTAD with the support of WHO and the European Commission), 18–19 March 2010, Buenos Aires, Argentina. All opinions, errors and omissions remain the responsibility of the author.

预览已结束，完整报告链接和二维码

<https://www.yunbaogao.cn/report/index/report?re>